Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parastoo Dahi

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Transplantation and Cellular Therapy|January 1, 2023
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell TherapyHarper Hubbeling, Emily A Silverman, Laure Michaud, et al.
Blood Advances|May 27, 2025
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantationIoannis Politikos, Samantha Brown, Joshua A Fein, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2015
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous LeukemiaDoris M Ponce, Patrick Hilden, Sean M Devlin, et al.
Transplantation and Cellular Therapy|May 24, 2026
Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignanciesMarina Gomez-Llobell, Silvia Escribano Serrat, Maria Bromberg, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research AnalysisNilanjan Ghosh, Reem Karmali, Vanderson Rocha, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Transplantation and Cellular Therapy|January 1, 2023
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell TherapyHarper Hubbeling, Emily A Silverman, Laure Michaud, et al.
Blood Advances|May 27, 2025
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantationIoannis Politikos, Samantha Brown, Joshua A Fein, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2015
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous LeukemiaDoris M Ponce, Patrick Hilden, Sean M Devlin, et al.
Transplantation and Cellular Therapy|May 24, 2026
Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignanciesMarina Gomez-Llobell, Silvia Escribano Serrat, Maria Bromberg, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research AnalysisNilanjan Ghosh, Reem Karmali, Vanderson Rocha, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Pageof 3